Cantab, MCCC To Fund Phogen Biotechnology For Third Year

11:04 EDT 4 Jul 2018 | Drug Discovery Online

Cantab Pharmaceuticals (Cambridge, UK) and Marie Curie Cancer Care (MCCC; London) will renew their financial support for Phogen (Cambridge, UK), a biotechnology company, for an additional year...

Original Article: Cantab, MCCC To Fund Phogen Biotechnology For Third Year

More From BioPortfolio on "Cantab, MCCC To Fund Phogen Biotechnology For Third Year"